Atherosclerosis
Volume 176, Issue 1 , Pages 57-62 , September 2004

Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on paraoxonase and platelet-activating factor acetylhydrolase in human plasma and tissue fluid

  • Takeshi Kujiraoka

      Affiliations

    • Department of Advanced Medical Technology and Development, BML Inc, 1361-1 Matoba, Kawagoe, Saitama 350-1101, Japan
    • ,
  • Hiroaki Hattori

      Affiliations

    • Department of Advanced Medical Technology and Development, BML Inc, 1361-1 Matoba, Kawagoe, Saitama 350-1101, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 49 232 0440; fax: +81 49 232 5480.
    • ,
  • Mayumi Ito

      Affiliations

    • Department of Advanced Medical Technology and Development, BML Inc, 1361-1 Matoba, Kawagoe, Saitama 350-1101, Japan
    • ,
  • M.Nazeem Nanjee

      Affiliations

    • Department of Cardiovascular Biochemistry, St. Bartholomew’s and the Royal London School of Medicine and Dentistry, London, UK
    • ,
  • Mitsuaki Ishihara

      Affiliations

    • Department of Advanced Medical Technology and Development, BML Inc, 1361-1 Matoba, Kawagoe, Saitama 350-1101, Japan
    • ,
  • Makoto Nagano

      Affiliations

    • Department of Advanced Medical Technology and Development, BML Inc, 1361-1 Matoba, Kawagoe, Saitama 350-1101, Japan
    • ,
  • Tadao Iwasaki

      Affiliations

    • Department of Advanced Medical Technology and Development, BML Inc, 1361-1 Matoba, Kawagoe, Saitama 350-1101, Japan
    • ,
  • C.Justin Cooke

      Affiliations

    • Department of Cardiovascular Biochemistry, St. Bartholomew’s and the Royal London School of Medicine and Dentistry, London, UK
    • ,
  • Waldemar L Olszewski

      Affiliations

    • Medical Research Center, Polish Academy of Sciences, Warsaw, Poland
    • ,
  • Irina P Stepanova

      Affiliations

    • Department of Cardiovascular Biochemistry, St. Bartholomew’s and the Royal London School of Medicine and Dentistry, London, UK
    • ,
  • Tohru Egashira

      Affiliations

    • Department of Advanced Medical Technology and Development, BML Inc, 1361-1 Matoba, Kawagoe, Saitama 350-1101, Japan
    • ,
  • Norman E Miller

      Affiliations

    • Department of Cardiovascular Biochemistry, St. Bartholomew’s and the Royal London School of Medicine and Dentistry, London, UK

Received 1 December 2003 ,Revised 1 March 2004 ,Accepted 19 March 2004.

References 

  1. Gordon DJ, Rifkind BM. High-density lipoprotein: the clinical implications of recent studies. N Engl. J. Med. 1989;321:1311–1316
  2. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 1995;115:243–253
  3. Watson AD, Navab M, Hama SY, et al.  Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995;95:774–782
  4. Lee C, Sigari F, Segrado T, et al.  All apo B-containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified. Modulation of lipoprotein bioactivity by platelet-activating factor acetylhydrolase. Arterioscler Thromb Vasc Biol. 1999;19:1437–1446
  5. Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J. Biol. Chem. 1987;262:4223–4230
  6. Stafforini DM, McIntyre TM, Carter ME, Prescott SM. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J. Biol. Chem. 1987;262:4215–4222
  7. Steinbrecher UP, Pritchard PH. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J Lipid Res. 1989;30:305–315
  8. Stremler KE, Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J. Biol. Chem. 1991;266:11095–11103
  9. Asano K, Okamoto S, Fukunaga K, et al.  Cellular source(s) of platelet-activating factor-acetylhydrolase activity in plasma. Biochem Biophys Res Commun. 1999;61:511–514
  10. Elstad MR, Stafforini DM, McIntyre TM, Prescott SM, Zimmerman GA. Platelet-activating factor actylhydrolase increases during macrophage differentiation. A novel mechanism that regulates accumulation of platelet-activating factor. J Biol Chem. 1989;264:8467–8470
  11. Nakahara H, Frenkel RA, Johnston JM. Secretion of platelet-activating factor acetylhydrolase following phorbol ester-stimulated differentiation of HL-60 cells. Arch Biochem Biophys. 1993;301:281
  12. La Du BN. Human serum paraoxonase/arylesterase. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press; 1992. p. 51–91.
  13. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129–135
  14. Watson AD, Berliner JA, Hama SY, et al.  Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882–2891
  15. Aviram M, Ronsenblat M, Bisgaier CL, et al.  Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 1998;101:1581–1590
  16. Kelso GJ, Stuart WD, Richter RJ, et al.  Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 1994;33:832–839
  17. Nanjee MN, Doran JE, Lerch PG, Miller NE. Acute effects of intravenous infusion of apo A-I/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol. 1999;19:979–989
  18. Nanjee MN, Cooke CJ, Garvin R, et al.  Intravenous apo A-I/lecithin discs increase pre-ß-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J. Lipid Res. 2001;42:1586–1593
  19. Nanjee MN, Cooke CJ, Olszewski WL, Miller NE. Lipid and apolipoprotein concentrations in prenodal leg lymph of fasted humans. Associations with plasma concentrations in normal subjects, lipoprotein lipase deficiency, and LCAT deficiency. J lipid Res. 2000;41:1317–1327
  20. Kujiraoka T, Oka T, Ishihara M, et al.  A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. J Lipid Res. 2000;41:1358–1363
  21. Kujiraoka T, Iwasaki T, Ishihara M, et al.  Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus. J Lipid Res. 2003;44:2006–2014
  22. Cooke CJ, Nanjee MN, Stepanova IP, Olszewski WL, Miller NE. Variations in lipid and apolipoprotein concentrations in human leg lymph: effects of posture and physical exercise. Atherosclerosis. 2004;173:39–45
  23. Kujiraoka T, Nanjee MN, Oka T, et al.  Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on LCAT, PLTP and CETP in plasma and peripheral lymph in humans. Arterioscler Thromb Vasc Biol. 2003;23:1653–1659
  24. Garin MB, Abbott C, Messmer S, et al.  Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J. 1994;304:549–554
  25. Packard CJ, O’Reilly DS, Caslake MJ, et al.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevension Study Group. N Engl J Med. 2000;343:1148–1155
  26. De Geest B, Stengel D, Landeloos M, et al.  Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on two lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis. Arterioscler Thromb Vasc Biol. 2000;20:E68–E75
  27. Tsimihodimos V, Karabina SA, Tambaki AP, et al.  Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J. Lipid Res. 2002;43:256–263
  28. Tsimihodimos V, Karabina SA, Tambaki AP, et al.  Atorvastatin preferentially reduces LDL-associated platelet-activating factoracetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol. 2002;22:306–311
  29. Shih DM, Gu L, Xia YR, et al.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284–287
  30. Shih DM, Xia YR, Wang XP, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem (2000) 17527–35.

PII: S0021-9150(04)00244-8

doi: 10.1016/j.atherosclerosis.2004.03.026

Atherosclerosis
Volume 176, Issue 1 , Pages 57-62 , September 2004

Article Tools

* Image Usage & Resolution